AKTX - Akari Therapeutics, Plc

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 534.54M
Enterprise Value 324.46M
Trailing P/E N/A
Forward P/E 1-6.78
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)N/A
Price/Book (mrq)23.77
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 6-1.33

Trading Information

Stock Price History

Beta (3Y Monthly) 2.01
52-Week Change 32.12%
S&P500 52-Week Change 32.16%
52 Week High 39.2000
52 Week Low 31.5600
50-Day Moving Average 31.9535
200-Day Moving Average 32.5381

Share Statistics

Avg Vol (3 month) 3752.09k
Avg Vol (10 day) 36.68M
Shares Outstanding 518.88M
Float 9.13M
% Held by Insiders 157.08%
% Held by Institutions 15.55%
Shares Short (Jul 31, 2019) 440.45k
Short Ratio (Jul 31, 2019) 40.44
Short % of Float (Jul 31, 2019) 4N/A
Short % of Shares Outstanding (Jul 31, 2019) 40.21%
Shares Short (prior month Jun 28, 2019) 467.62k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 210/1
Last Split Date 3Sep 17, 2015

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-66.95%
Return on Equity (ttm)-201.47%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -18.34M
Net Income Avi to Common (ttm)-17.67M
Diluted EPS (ttm)-1.1370
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)6.15M
Total Cash Per Share (mrq)0.39
Total Debt (mrq)N/A
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)1.13
Book Value Per Share (mrq)0.08

Cash Flow Statement

Operating Cash Flow (ttm)-17.95M
Levered Free Cash Flow (ttm)-12.35M